Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL35AP17 is a processed pseudogene of the ribosomal protein L35a (RPL35A) gene family. Unlike the functional RPL35A gene—which encodes a ribosomal protein of the 60S subunit essential for protein synthesis[2][3][7]—RPL35AP17 does not produce a functional protein. Pseudogenes are common in ribosomal protein families, resulting from genome duplication events and subsequent loss of function[3][7]. There is no evidence from current literature that RPL35AP17 plays a direct role in biology or disease, nor is it considered a therapeutic target or biomarker. If you meant the functional gene (RPL35A), it is involved in protein synthesis, cell cycle regulation, and is clinically associated with disorders like Diamond-Blackfan anemia[2][3][7]. However, RPL35AP17 itself is a pseudogene with no demonstrated function or clinical relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein L35a pseudogene 17 (RPL35AP17).